NASDAQ:SAVA Cassava Sciences - SAVA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $23.71 -2.00 (-7.78%) (As of 03/22/2023 03:52 PM ET) Add Compare Share Share Today's Range$23.58▼$25.7350-Day Range$24.70▼$36.4452-Week Range$13.84▼$51.59Volume1.46 million shsAverage Volume1.33 million shsMarket Capitalization$989.89 millionP/E RatioN/ADividend YieldN/APrice Target$54.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Cassava Sciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside129.3% Upside$54.33 Price TargetShort InterestBearish28.69% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$302,193 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.76) to ($3.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector616th out of 983 stocksPharmaceutical Preparations Industry295th out of 478 stocks 3.0 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.33, Cassava Sciences has a forecasted upside of 129.3% from its current price of $23.70.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted28.69% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Cassava Sciences has recently increased by 3.87%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 2.2 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cassava Sciences this week, compared to 3 articles on an average week.Search InterestOnly 46 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $302,193.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.10% of the stock of Cassava Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.51% of the stock of Cassava Sciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to decrease in the coming year, from ($0.76) to ($3.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -12.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -12.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cassava Sciences (NASDAQ:SAVA) StockCassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.Read More Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SAVA Stock News HeadlinesMarch 17, 2023 | finance.yahoo.com3 Short-Squeeze Stocks to Keep on Your RadarMarch 12, 2023 | seekingalpha.comA Comparison Between Cassava Sciences' Simufilam, Aricept, Anavex's Blarcamesine, And Panax Ginseng For The Treatment Of Alzheimer's DiseaseMarch 22, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 9, 2023 | msn.comThis Insider Just Spiked Investors’ Interest in Cassava (NASDAQ:SAVA) StockMarch 8, 2023 | msn.comCassava Sciences up 9% on director's ~$2.3M share purchasesMarch 8, 2023 | benzinga.comCassava Sciences shares are trading higher following the purchase of 88,841 shares by a company director.March 8, 2023 | markets.businessinsider.comWhy Cassava Sciences Stock Is Surging After HoursMarch 6, 2023 | finance.yahoo.comThe three-year returns have been massive for Cassava Sciences (NASDAQ:SAVA) shareholders despite underlying losses increasingMarch 22, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 5, 2023 | seekingalpha.comCassava Sciences: Open Label Study Data Unconvincing But Indicative Of Good ThingsMarch 3, 2023 | finance.yahoo.comQ4 2022 Lexicon Pharmaceuticals Inc Earnings CallFebruary 28, 2023 | finanznachrichten.deCassava Sciences, Inc.: Cassava Sciences Reports Full-year 2022 Financial Results and Operating UpdatesFebruary 28, 2023 | finance.yahoo.comCassava Sciences Reports Full-year 2022 Financial Results and Operating UpdatesFebruary 8, 2023 | msn.comCassava Sciences plans to complete enrollment for phase simufilam studies by year endFebruary 8, 2023 | finance.yahoo.comCassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s DiseaseFebruary 1, 2023 | finance.yahoo.com3 Big Reasons to Sell Cassava Sciences Stock Right NowJanuary 31, 2023 | benzinga.comIf You Invested $100 In This Stock 5 Years Ago, You Would Have $400 TodayJanuary 30, 2023 | seekingalpha.comCassava Sciences And Alzheimer's Disease: Unravelling The DataJanuary 27, 2023 | seekingalpha.comCassava Sciences' Data Once Again MisunderstoodJanuary 26, 2023 | seekingalpha.comCassava Sciences: Data For Mild Alzheimer's Disease Patients Provides Good Risk/Reward ProfileJanuary 24, 2023 | msn.comTesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention TodayJanuary 24, 2023 | investorplace.comWhy Is Cassava Sciences (SAVA) Stock Down 20% Today?January 24, 2023 | msn.comCassava Sciences Shares Fall As Alzheimer's Candidate Worsens Patients With Moderate DiseaseJanuary 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Cassava Sciences (SAVA)January 24, 2023 | msn.comCassava Sciences falls 17% after reporting mid-stage data for Alzheimer’s candidateJanuary 24, 2023 | finance.yahoo.comCassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With InvestorsJanuary 24, 2023 | finance.yahoo.comCassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s DiseaseSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SAVA Company Calendar Last Earnings11/10/2021Today3/22/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees24Year FoundedN/APrice Target and Rating Average Stock Price Forecast$54.33 High Stock Price Forecast$124.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+111.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.59% Return on Assets-33.38% Debt Debt-to-Equity RatioN/A Current Ratio29.91 Quick Ratio29.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.68 per share Price / Book4.53Miscellaneous Outstanding Shares41,750,000Free Float37,532,000Market Cap$1.07 billion OptionableNot Optionable Beta-0.10 Key ExecutivesRemi BarbierChairman, President & Chief Executive OfficerEric J. SchoenChief Financial OfficerJames W. KupiecChief Medical OfficerMichael ZamlootSenior Vice President-Technical OperationsGeorge B. ThorntonSenior Vice President-TechnologyKey CompetitorsAvid BioservicesNASDAQ:CDMOZentalis PharmaceuticalsNASDAQ:ZNTLMannKindNASDAQ:MNKDMoonLake ImmunotherapeuticsNASDAQ:MLTXVerve TherapeuticsNASDAQ:VERVView All CompetitorsInsiders & InstitutionsRichard BarryBought 11,565 shares on 3/6/2023Total: $302,193.45 ($26.13/share)Morgan StanleySold 2,508 shares on 2/15/2023Ownership: 0.538%State of Wisconsin Investment BoardSold 448 shares on 2/15/2023Ownership: 0.095%MetLife Investment Management LLCSold 981 shares on 2/15/2023Ownership: 0.049%Virtu Financial LLCSold 3,064 shares on 2/15/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions SAVA Stock - Frequently Asked Questions Should I buy or sell Cassava Sciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SAVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares. View SAVA analyst ratings or view top-rated stocks. What is Cassava Sciences' stock price forecast for 2023? 3 analysts have issued 12-month price objectives for Cassava Sciences' shares. Their SAVA share price forecasts range from $11.00 to $124.00. On average, they predict the company's share price to reach $54.33 in the next twelve months. This suggests a possible upside of 112.2% from the stock's current price. View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts. How have SAVA shares performed in 2023? Cassava Sciences' stock was trading at $29.54 at the beginning of 2023. Since then, SAVA stock has decreased by 13.3% and is now trading at $25.60. View the best growth stocks for 2023 here. When is Cassava Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our SAVA earnings forecast. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.09. What ETFs hold Cassava Sciences' stock? ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dynamic Biotechnology & Genome ETF (PBE), iShares Neuroscience and Healthcare ETF (IBRN), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares U.S. Pharmaceuticals ETF (IHE). When did Cassava Sciences' stock split? Cassava Sciences shares reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA). What is Cassava Sciences' stock symbol? Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA." Who are Cassava Sciences' major shareholders? Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Jefferies Financial Group Inc. (0.00%), Geode Capital Management LLC (1.77%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%), Norges Bank (0.82%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Eric Schoen, James William Kupiec, Remi Barbier, Richard Barry and Sanford Robertson. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cassava Sciences' stock price today? One share of SAVA stock can currently be purchased for approximately $25.60. How much money does Cassava Sciences make? Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.07 billion. The company earns $-76,250,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. How can I contact Cassava Sciences? Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for the company is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at ir@paintrials.com, or via fax at 512-501-0414. This page (NASDAQ:SAVA) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.